Training & Education - Treatment & Management Summary
- Therapeutic phlebotomy is the preferred treatment for reducing iron stores in hemochromatosis patients.
- For a patient who has no evident tissue or organ damage, proper disease management may result in normal long-term outcome and life expectancy.
- Clinicians must design phlebotomy treatment regimens that are individualized to each patient and account for age, gender, weight, health, and likelihood of compliance.
- Serum ferrinin levels should be measured after each additional one or two phlebotomy treatments once the value is ≤ 100 ng/mL.
- Careful monitoring of each patient throughout treatment is imperative. If treatment is too aggressive, anemia may result.
- Continued lifetime monitoring is key to appropriate management.
- Phlebotomy should be performed throughout a patient’s life to keep the serum ferritin level between 25 and 50 ng/mL.
- Download a print-friendly "Phlebotomy Information for Patients with Hemochromatosis."
- Hemochromatosis cannot be treated by diet alone.
- The following dietary modifications for patients are suggested:
- Avoid iron supplements.
- Read the label of multivitamins to make sure they do not contain iron.
- Limit vitamin C supplementation to 500 mg/day.
- Avoid eating raw shellfish.
- Avoid more than moderate alcohol consumption. Patients with liver damage should avoid alcohol.
- Download a print-friendly "Diet information for patients with hemochromatosis."
This is an optional self-quiz and is not required for continuing education credit.
- Centers for Disease Control and Prevention
National Center on Birth Defects and Developmental Disabilities
Division of Blood Disorders
1600 Clifton Road
Atlanta, GA 30333
TTY: (888) 232-6348
- Contact CDC-INFO